BRIEF-Novo Nordisk Says Diabetes Drug Ozempic Has Been Approved In The EU

by Reuters
Friday, 9 February 2018 11:41 GMT

Feb 9 (Reuters) - NOVO NORDISK:

* OZEMPIC (SEMAGLUTIDE) APPROVED IN EU FOR TREATMENT OF TYPE 2 DIABETES​

* SAYS ‍OZEMPIC HAS BEEN APPROVED IN EU FOR USE IN A MULTI-DOSE PEN, HOWEVER, NOVO INTENDS TO SUBMIT A VARIATION APPLICATION TO EUROPEAN MEDICINES AGENCY (EMA) SEEKING APPROVAL OF AN UPDATED OZEMPIC PEN OFFERING

* OZEMPIC WAS APPROVED BY THE U.S. FDA ON 5 DECEMBER 2017 SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Reporting by Stine Jacobsen)

Our Standards: The Thomson Reuters Trust Principles.